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Abstract
Background: Niemann-Pick type C (NPC) disease is a fatal neurodegenerative disorder caused most commonly by a defect in
theNPC1proteinandcharacterizedbywidespreadintracellularaccumulationofunesterifiedcholesterolandglycosphingolipids
(GSLs). While current treatment therapies are limited, a few drugs tested in Npc1
2/2 mice have shown partial benefit. During a
combination treatment trial using two such compounds, N-butyldeoxynojirimycin (NB-DNJ) and allopregnanolone, we noted
increased lifespan for Npc1
2/2 mice receiving only 2-hydroxypropyl-b-cyclodextrin (CD), the vehicle for allopregnanolone. This
finding suggested that administration of CD alone, but with greater frequency, might provide additional benefit.
Methodology/Principal Findings: Administration of CD to Npc1
2/2 mice beginning at either P7 or P21 and continuing every
other day delayed clinical onset, reduced intraneuronal cholesterol and GSL storage as well as free sphingosine accumulation,
reducedmarkers ofneurodegeneration,andled tolongersurvival thanany previoustreatment regime.Wereasonedthatother
lysosomal diseases characterized by cholesterol and GSL accumulation, including NPC disease due to NPC2 deficiency, GM1
gangliosidosis and mucopolysaccharidosis (MPS) type IIIA, might likewise benefit from CD treatment. Treated Npc2
2/2 mice
showed benefits similar to NPC1 disease, however, mice with GM1 gangliosidosis or MPS IIIA failed to show reduction in
storage.
Conclusions/Significance: Treatment with CD delayed clinical disease onset, reduced intraneuronal storage and secondary
markers of neurodegeneration, and significantly increased lifespan of both Npc1
2/2 and Npc2
2/2 mice. In contrast, CD
failed to ameliorate cholesterol or glycosphingolipid storage in GM1 gangliosidosis and MPS IIIA disease. Understanding the
mechanism(s) by which CD leads to reduced neuronal storage may provide important new opportunities for treatment of
NPC and related neurodegenerative diseases characterized by cholesterol dyshomeostasis.
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Introduction
Niemann-Pick type C (NPC) disease is an autosomal recessive
neurodegenerative disorder characterized by accumulation of
unesterified cholesterol and glycosphingolipids (GSLs), such as
GM2 and GM3 ganglioside [1,2]. Patients with this fatal disease
develop an ataxic gait and motor dysfunction, typically preceded by
vertical gaze palsy and organomegaly, and later accompanied by
seizures and dementia. On a cellular level, neurons exhibit complex
disease-related morphological alterations including formation of
meganeurites, ectopic dendrites, and axonal spheroids [3]. NPC
disease is also characterized by neurodegeneration, including
the presence of intracellular protein aggregates in the form of
neurofibrillarytangles,and awell-definedpatternedlossofcerebellar
Purkinje cells [4]. Defects in a transmembrane protein, NPC1,
account for approximately 95% of cases with the remainder
involving a soluble protein, NPC2 [2]. Both proteins have been
shown to bind cholesterol [5–8] and are found in the late
endosomal/lysosomal (LE/LY) system. Here they are thought to
function cooperatively in facilitating egress of cholesterol from LE/
LY to other sites in the cell [9,10]. Cholesterol sequestration in NPC
disease is generally believed to be followed secondarily by GSL
accumulation, but restricting synthesis of complex gangliosides has
been shown to reduce cholesterol storage in most neurons [11,12].
Therapeutic options for NPC disease are quite limited.
Substrate reduction therapy (SRT) utilizes drugs that reduce the
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known to accumulate in storage diseases [13]. In 2001, Zervas and
colleagues demonstrated that daily administration of an inhibitor of
GSL synthesis, N-butyldeoxynojirimycin (NB-DNJ or miglustat) to
Npc1
2/2 mice resulted in a reduction in accumulation of GSLs, a
delay in onset of clinical signs, and a 30% increase in lifespan [14].
More recently, miglustat has also been shown in a randomized
controlled study to stabilize or improve clinical markers of NPC
disease in patients treated for 12 months [15] and in January of
2009, miglustat (ZavescaH) was approved by the European
Medicines Agency for use in treatment of neurological symptoms
in patients with NPC disease. A second therapeutic agent tested in
Npc1
2/2 mice was allopregnanolone, a neurosteroid shown
deficient in the central nervous system (CNS) of Npc1
2/2 mice
[16]. Administration of allopregnanolone solubilized in
2-hydroxypropyl-b-cyclodextrin (CD) to Npc1
2/2 mice at postnatal
day7(P7)wasreportedtobebeneficial,with treated mice exhibiting
delayed clinical onset, extended life span, and reduced ganglioside
accumulation. This therapeutic approach has been referred to as
by-product replacement therapy or BRT, since the strategy was
thought to replace missing or deficient products needed for normal
cellular functioning [17]. Based on these positive results, we
reasoned that a combination therapy utilizing both miglustat and
allopregnanolone might work synergistically to ameliorate NPC1
disease. While this combination therapy did prove additive, our
studies revealed that the vehicle, CD, also provided significant
benefit. This finding coincided with published observations that
single dose CD increased the lifespan of Npc1
2/2 mice (18).
Additionalstudiesreported herefurther establishthat CDtreatment
alone dramatically ameliorates NPC disease and questions the
efficacy of allopregnanolone administered without CD. A recent
publication investigating the effects of a single injection of CD with
orwithout allopregnanolone inNPC1disease reported no additional
benefit of allopregnanolone in reducing cholesterol accumulation in
the liver and brain as well as a reduction in markers of
neurodegeneration, but did reconfirm the increase in lifespan of
CD-treated Npc1
2/2 mice. [19]. Our current report further
demonstrates that sequestration of GSLs, sphingosine, and choles-
terol is significantly reduced in neurons of CD-treated Npc1
2/2 mice
and that chronic treatment with CD leads to the most significant
amelioration of NPC disease in the murine model seen to date.
Results
Combination SRT and BRT therapy in Npc1
2/2 mice
provides synergistic effect
Npc1
2/2 mice treated with a combination therapy of NB-DNJ
(administered daily starting at P10) and allopregnanolone/CD
(administered weekly starting at P7) showed a 2 week delay in
onset of clinical signs (ataxic gait, tremor) when compared to
untreated (given no injections) or vehicle (saline or CD) treated
Npc1
2/2 mice. Untreated Npc1
2/2 mice began a precipitous
weight loss beginning at 6 weeks of age, while combination-treated
Npc1
2/2 mice gradually lost weight starting at 14 weeks (Fig. 1A).
Combination-treated Npc1
2/2 mice lived significantly longer than
did untreated or vehicle-injected (saline or CD) Npc1
2/2 mice
(Fig. 1B). We noted, however, that Npc1
2/2 mice receiving CD
alone also lived significantly longer than untreated Npc1
2/2 mice
(median age: untreated Npc1
2/2 mice: 79 days; CD-treated
Npc1
2/2 mice: 118 days; p,0.0001). Correspondingly, weight loss
in CD-injected Npc1
2/2 mice was delayed by approximately 3
weeks. Analysis of cholesterol accumulation by filipin labeling
revealed a decrease in cholesterol storage in neocortical neurons of
combination and CD-treated Npc1
2/2 mice compared to
Figure 1. Combination treatment using NB-DNJ and allopreg-
nanolone/CD in Npc1
2/2 mice. (A) Average weight over time for each
treatment group shown for males and females separately. (B) Survival of
each treatment group. Median survival of Npc1
2/2 mice: no treatment,
79 days; CD (weekly), 118 days; Miglustat (daily), 123 days; Allopregna-
nolone/CD (weekly), 146 days; Combination therapy (Miglustat +
Allopregnanolone/CD), 152 days.
doi:10.1371/journal.pone.0006951.g001
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2/2 mice (Fig. 2A). Like cholesterol, GM2 and
GM3 gangliosides are well characterized storage components of
NPC disease, but their levels in wild-type (WT) brain are
negligible. Immunohistochemical (IHC) analysis of GM2 and
GM3 gangliosides in the neocortex of Npc1
2/2 mice yielded
similar results in terms of cholesterol storage, with combination
and CD-treated mice exhibiting less ganglioside accumulation
than untreated mice (Fig. 2B, C). Comparison of cerebellum in
age-matched untreated and combination-treated Npc1
2/2 mice
revealed a striking rescue of Purkinje cells in treated animals as
evidenced by calbindin labeling (Fig. 2D). While surviving
Purkinje cells were confined largely to lobule X in untreated
Npc1
2/2 mice, those receiving the combination drug treatment
still had Purkinje cells present in all lobules. GM2 accumulation
was present mainly in the granular cell layer of Npc1
2/2 mice, but
combination-treated Npc1
2/2 animals had less GM2 staining than
Npc1
2/2 controls (untreated and saline; data not shown).
Short-term administration of CD alone reduces storage in
Npc1
2/2 mice
The discovery that CD alone (without allopregnanolone) reduced
intraneuronal storage and increased longevity of Npc1
2/2 mice led
us to perform a series of studies to address its possible role as a
therapeutic agent in and of itself. Npc1
2/2 mice were treated
beginning at P7 with injections of CD every other day for 2 weeks.
Route of CD administration was either subcutaneous (SC) or
intraperitoneal (IP) and while both had a similar outcome, SC
administration seemed to be slightly more efficacious (Fig. S1). At 2
weeks ofage,mice wereterminated to evaluate cholesteroland GSL
storage. Results showed little to no accumulation of cholesterol in
neurons of the cerebral cortex in 22-day old treated Npc1
2/2 mice,
whereas age-matched untreated Npc1
2/2 mice exhibited consider-
able filipin-labeling (Fig. 3A). CD treatment also diminished
accumulation of gangliosides, such that GM2 and GM3 storage in
the neocortex of treated Npc1
2/2 mice was nearly absent compared
to readily detectable storage in untreated Npc1
2/2 mice (Fig. 3B;
GM3 not shown). A parallel quantitative biochemical study of
gangliosides in cerebrum of these mice revealed strikingly different
patterns in the untreated and treated Npc1
2/2 animals, with a near
normalization to WT levels in the concentrations of both GM2 and
GM3 after CD treatment (Fig. 3C). At this age, GM2 has already
reached itsnearmaximal levelintheuntreated mutants,whileGM3
is at about 50% of its maximum (unpublished data, MT Vanier).
Ultrastructural analysis revealed that cortical neurons of a 22-day
old CD-treated Npc1
2/2 mouse had little to no evidence of
polymembranous cytoplasmic bodies (PCBs) characteristic of NPC
disease (Fig. 3D), a finding consistent with the lack of detectable
cholesterol and ganglioside storage.
Analysis of cerebellar cortex from 22-day old untreated Npc1
2/2
mice revealed that nearly every Purkinje cell, as well as presumptive
neurons in both the granule and molecular cell layers, showed
evidence of cholesterol accumulation by filipin labeling (Fig. 3E).
However, most Purkinje cells in age-matched CD-treated Npc1
2/2
mice lacked cholesterol storage and only a small number of filipin-
positive neurons were present in the granule cell layer. IHC analysis
of GM2 in the cerebellum of untreated Npc1
2/2 mice revealed
prominent accumulation throughout the granule cell layer and
occasional storage in the molecular cell layer, while age-matched
CD-treated Npc1
2/2 mice exhibited less accumulation in both the
granule and molecular cell layers (data not shown). Levels of the
autophagosomemarkerLC3-II werealsoaffected byCDtreatment,
as evidenced by western blot analysis of the cerebellum. Increased
levels of LC3-II havepreviously been shown in the CNS of Npc1
2/2
mice suggesting alterations in the degradative mechanism known as
macroautophagy [20,21]. Our results confirmed this increase in
LC3-II and additionally, showed that levels in CD-treated Npc1
2/2
mice were normalized to those seen in WT controls (Fig. 3F).
These findings indicating that CD significantly limits cholesterol
and ganglioside storage in neurons of young Npc1
2/2 mice led us
to carry out two additional studies, one examining the ability of
allopregnanolone alone to ameliorate disease progression and the
other to determine the efficacy of long-term CD therapy.
Allopregnanolone without CD does not appear beneficial
The initial combination study suggested not only a beneficial
effect of CD, but also a possible small additional benefit of
allopregnanolone with CD (Fig. 1A; median age: CD-treated
Npc1
2/2 mice: 118 days; Allopregnanolone/CD-treated Npc1
2/2
mice: 146 days; p,0.0038). To determine whether there was any
beneficial impact of allopregnanolone alone on Npc1
2/2 mice, we
administered allopregnanolone using vehicles other than CD
(dimethylsulfoxide[DMSO]orcorn oil) ora reduced concentration
of CD (5% CD solution). Mice were given weekly injections
following the same protocol used in the combination study, with the
exception of allopregnanolone/corn oil (total of three injections
given at P7, P14, and P21). Onset of ataxic gait occurred in all
treated and untreated Npc1
2/2 mice at 6–7 weeks of age and there
wasno increase inlifespan of the allopregnanolone-treated Npc1
2/2
mice (vehicle: corn oil or DMSO) compared to vehicle injected
Npc1
2/2 controls. Npc1
2/2 mice treated with allopregnanolone
solubilized in 5% CD did live significantly longer than mice
receiving the other allopregnanolone solutions or corn oil and
DMSO vehicles, but so too did the control animals receiving only
5% CD (Fig. 4A). Analysis of cholesterol and gangliosides did not
demonstrate detectable storage reductions between the allopregna-
nolone-treated Npc1
2/2 mice versus their respective vehicle-
injected controls. Collectively, these results suggest that the
beneficial effects observed in the combination trial for allopregna-
nolone-treated Npc1
2/2 mice are due largely to the vehicle, CD,
and that allopregnanolone may provide only a small additional
benefit when administered in 20% CD.
Chronic CD injections ameliorate NPC1 disease in mice
Using the same treatment regimen described earlier (injections
given every other day), Npc1
2/2 and WT mice were administered
CD beginning at P7 and continuing to end-stage disease, when
affected mice showed a hunched posture, severe gait disturbance,
and/or weight loss greater than 30% of peak weight. Behaviorally,
onset of ataxia in untreated Npc1
2/2 mice occurred between 6 and
7 weeks of age, while CD treatment delayed onset by 3 weeks, such
that treated Npc1
2/2 mice became ataxic between 9 and 10 weeks
of age. Furthermore, abrupt weight loss in untreated Npc1
2/2
mice began to occur around 7 weeks of age, while treated Npc1
2/2
mice exhibited a gradual decline in weight beginning at 10 to 13
weeks of age (Fig. 4B). Every-other-day treated Npc1
2/2 mice on
average lived longer than those on the original combination
therapy, though the difference was not significant (Fig. 1B and 4C;
median age: combination-treated Npc1
2/2 mice: 152 days; CD-
treated Npc1
2/2 mice began at P7: 185 days; p,0.2138).
Filipin labeling of neocortical neurons in CD-treated Npc1
2/2
mice at end-stage revealed less cholesterol storage compared to
their untreated counterparts, in spite of their significant age
differences (Fig. 5A). There was a reduction in both the number of
neurons that showed cholesterol storage and the amount of
cholesterol in individual neurons, some of which appeared to have
little or no accumulation (Fig. 5B). Confocal analysis of treated
Npc1
2/2 mouse brain showed that many cholesterol negative
Cyclodextrin in NPC Disease
PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e6951Figure 2. Cholesterol and ganglioside immunohistochemistry (IHC) of Npc1
2/2 and WT mice in the combination treatment study. (A)
Filipin labeling of unesterified cholesterol (seen as white areas in image) in the neocortex of age-matched untreated and treated Npc1
2/2 and WT mice
(all mice between 75 and 81 days of age) revealed less cholesterol accumulation of treated Npc1
2/2 mice (second, third, and fourth panels) when
compared to control Npc1
2/2 mice (fifth panel). WT mice do not exhibit cholesterol accumulation (first panel). Each panel here and in (B) and (C) shows
layers II (top) through VI (bottom) of the cerebral cortex. (B) IHC of GM2 ganglioside (visualized as brown punctae within cells) was also characterized by
reduced GM2 storage in all treated Npc1
2/2 mice. (C) IHC of GM3 ganglioside (again seen as brown punctae within cells) showed results similar to GM2.
(D)TreatedNpc1
2/2 micehadmore remainingPurkinje cells(brownareasincerebellarimages)than diduntreatedNpc1
2/2 mice;however,treatedmice
still had Purkinje cell loss when compared to WT mice. Anti-calbindin antibody labels Purkinje cell bodies and dendritic arbors, while the Nissl
counterstain (purple) labels all neuronal cell bodies. Images taken at 20X (A), 10X (B, C), and 2X (D); scale bars 20 mm (A), 50 mm (B, C), and 400 mm (D).
doi:10.1371/journal.pone.0006951.g002
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(Fig. 5C).
IHC staining of both GM2 and GM3 gangliosides revealed
less accumulation in CD-treated Npc1
2/2 mice compared to age-
matched Npc1
2/2 controls (Fig. 5D, GM3 not shown). Biochem-
ical analysis of gangliosides (Fig. 5E) corroborated and extended
this finding. In the cerebrum of CD-treated Npc1
2/2 mice, the
increase in GM2 and GM3 levels, while not significant at 22 days
(Fig. 3C), remained very moderate at 90 days (115 and 76 nmol/g
for GM2 and GM3, respectively, compared with 474619 and
Figure 3. Short term (2 week) CD study in Npc1
2/2 mice. (A) Filipin labeling of unesterified cholesterol in the neocortex of untreated and CD-
treated Npc1
2/2 mice revealed dramatically less cholesterol accumulation in CD-treated mice at 22 days of age. Mice were administered SC injections
of CD every other day for 2 weeks starting at P7. (B) IHC of untreated and CD-treated Npc1
2/2 mice also revealed less GM2 storage present in CD-
treated mice (similar finding for GM3, not shown). (C) Biochemical analysis of ganglioside levels further corroborated the reduction in GM2 and GM3
seen with IHC analysis. (D) Ultrastructural analysis of neocortical neurons in Npc1
2/2 untreated and CD-treated mice showed remarkably normal
neuronal morphology in CD-treated mice. (E) Filipin labeling of unesterified cholesterol in the cerebellum of untreated and CD-treated Npc1
2/2 mice
indicated little to no cholesterol accumulation present within Purkinje cells of CD-treated mice; cerebellar layers: molecular cell layer (MCL), Purkinje
cell layer (PCL), and granular cell layer (GCL). (F) Western blot analysis of LC3-II, an autophagosome marker, revealed less LC3-II present in CD-treated
Npc1
2/2 as compared to untreated Npc1
2/2 mice. Images taken at 20X (A, E) and 10X (B); scale bars 20 mm (A, E), 50 mm (B), 1 mm (D).
doi:10.1371/journal.pone.0006951.g003
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2/2
mice; mean 6 SD). The two treated mice at end-stage (190 and
223 days) still showed concentrations of GM2 and GM3
gangliosides approximately half of those in end-stage untreated
Npc1
2/2 mice. Neuro-inflammation is also an important compo-
nent of many lysosomal diseases [22], and upon IHC staining of
CD68, a CNS inflammatory marker, we noted reduced labeling in
brains of end-stage CD-treated Npc1
2/2 mice compared to end-
stage untreated Npc1
2/2 mice (data not shown). Ultrastructurally,
although neurons of CD-treated Npc1
2/2 mice often had PCBs,
they appeared to be less abundant than in untreated Npc1
2/2 mice
(Fig. 5F).
Cholesterol storage was observed in all Purkinje cells of the
cerebellum in treated and untreated Npc1
2/2 mice. At end-stage,
remaining Purkinje cells were observed almost exclusively in lobule
X, whereas in treated Npc1
2/2 mice (age-matched to end-stage
untreated Npc1
2/2 mice), rescued Purkinje cells were routinely
observed in other lobules. IHC analysis of GM2 ganglioside
revealed prominent accumulation throughout the granule cell
layer and occasional storage within the molecular cell layer of end-
stage untreated Npc1
2/2 mice cerebella. CD-treated Npc1
2/2
mice exhibited this same pattern but with reduced GM2
accumulation (data not shown).
As in the short term study, biochemical analysis of LC3-II in the
cerebellum revealed that CD-treated Npc1
2/2 mice had levels
similar to WT, while untreated Npc1
2/2 mice showed an increase
in LC3-II levels compared to WT (Fig. 5G).
In addition to brain analyses, we examined peripheral tissues
including kidney, liver, and lung for changes induced by treatment
with CD. Filipin analysis of kidneys from the chronic CD treatment
study revealed no obvious differences between treated and
untreated Npc1
2/2 mice, even though CD is thought to be excreted
mainly intact in urine [23] (Fig. S2A). H&E staining of kidney also
revealed no obvious changes with CD treatment in either Npc1
2/2
or WT mice (Fig. S3A). Cholesterol labeling of the liver of untreated
Npc1
2/2 mice occurred primarily in hepatocytes, with treated mice
showing a shift in cholesterol sequestration to apparent Kupffer
cells, a change also observed when comparing WT untreated and
treated mice (Fig. S2B). Large, lipid-laden hepatocytes were seen in
the untreated Npc1
2/2 liver tissue but were largely undetectable in
CD-treated Npc1
2/2 liver as visualized with H&E staining (Fig.
S3B). A parallel biochemical study of liver lipids revealed a near
normalization of the levels of unesterified cholesterol and
sphingomyelin, as well as of bis(monoacylglycero)phosphate
(BMP) and neutral glycolipids (glucosylceramide and lactosylcer-
amide) in chronic CD-treated Npc1
2/2 mice (Fig. S4). Filipin
analysis of lung revealed cholesterol laden cells in both untreated
and CD-treated age-matched Npc1
2/2 mice (87 and 90 days,
respectively), with a seemingly greater number of cholesterol
positive cells present in the CD-treated animal. Lung from a CD-
treated Npc1
2/2 mouse at end-stage disease (223 days) had a
consolidated appearance with more lipid laden cells and cholesterol
deposits throughout the tissue than either of the previous Npc1
2/2
mice (Fig. S2C). While H&E staining revealed the occasional
presence of macrophages in untreated Npc1
2/2 lung, CD-treated
Npc1
2/2 mouse lung showed more macrophages present and also
increasing macrophage infiltration the longer CD-treatment was
continued (Fig. S3C). Similar lipid-laden macrophages were not
evident in either CD-treated or untreated WT lung.
In addition to starting CD treatment at 7 days of age, some
Npc1
2/2 mice were treated shortly after weaning (P21–P25; post-
weaning treated). Even with this two week delay, benefits similar to
those seen in Npc1
2/2 mice treated beginning at P7 were still
evident (Fig. 4C). Onset of clinical signs in Npc1
2/2 mice in which
Figure 4. Chronic allopregnanolone and chronic CD treatment
studies in Npc1
2/2 mice. (A) Survival of untreated and allopregna-
nolone-treated Npc1
2/2 mice using different vehicles for allopregna-
nolone. Median survival of Npc1
2/2 mice: DMSO, 84 days; Allo/DMSO,
83 days; Corn Oil, 81 days; Allo/Corn Oil, 88 days; 5% CD, 114 days; Allo/
5% CD, 121 days. (B) Average weight over time for untreated and
chronically CD-treated Npc1
2/2 and WT mice. Weights of untreated and
CD-treated WTs were averaged for each gender as there was no
significant difference between treatments (p,0.8125). (C) Survival of
untreated and CD-treated Npc1
2/2 and WT mice showing effects of
different start times. Median survival of Npc1
2/2 mice: no treatment, 83
days; CD (every other day, start at P7), 185 days; CD (every other day,
start at P21), 149 days. Treatment initiated at P7 appeared more
efficacious, although lifespan was not significantly longer when
compared to treatment initiated at P21 (p,0.1870).
doi:10.1371/journal.pone.0006951.g004
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PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e6951Figure 5. Chronic CD treatment study in Npc1
2/2 mice. (A) Filipin labeling of unesterified cholesterol in the neocortex of untreated (end-stage,
78 days old) and CD-treated (start at P21; end-stage, 197 days old) Npc1
2/2 mice showed reduced cholesterol accumulation in a CD-treated mouse.
(B) Higher magnification of neocortex in same CD-treated Npc1
2/2 animal as previous panel, showed presence of neurons with cholesterol
accumulation while neighboring cells lacked this storage. (C) Confocal microscopy further revealed that gangliosides and cholesterol appeared to
always co-sequester within neurons in an untreated Npc1
2/2 mouse (end-stage, 78 days old; upper panel). However, some neocortical neurons in a
CD-treated Npc1
2/2 mouse (start at P7; end-stage, 182 days old; lower panel) had little to no detectable cholesterol accumulation, yet still exhibited
ganglioside storage. Cholesterol (red, visualized with BC Theta), GM2 (blue), and GM3 (green); n denotes nucleus of single neuron shown in each
image. (D) IHC of untreated and CD-treated Npc1
2/2 mice (same mice as A), revealed less GM2 storage (also GM3, not shown) in the neocortex of a
CD-treated mouse. (E) Biochemical analysis of ganglioside levels further corroborated the reduction in GM2 and GM3 seen with IHC. Data from WT
and untreated mutant mice represent mean 6 SD. (F) Ultrastructural analysis of neocortical neurons in untreated and CD-treated Npc1
2/2 mice (same
mice as C) revealed presence of PCBs in both groups, but CD-treated mice appeared to have fewer of these storage bodies. (G) Western blot analysis
of LC3-II in 85 day old untreated and CD-treated (start at P21) Npc1
2/2 and WT mice revealed a reduction in LC3-II levels in the CD-treated Npc1
2/2
mouse. Images taken at 20X (A), 40X (B), 63X (C), and 10X (D); scale bars 20 mm (A, B), 2 mm (C), 50 mm (D), 1 mm (F).
doi:10.1371/journal.pone.0006951.g005
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increased, although these mice did show greater variability than
mice started at P7. Even though the median lifespan of these
Npc1
2/2 mice treated post-weaning was less than that of mice
started on treatment at P7, there was no significant difference
(median age: CD-treated Npc1
2/2 mice starting post-weaning: 149
days; CD-treated Npc1
2/2 mice starting at P7: 185 days;
p,0.1870). Cholesterol and ganglioside analysis of post-weaning
treated Npc1
2/2 mice revealed reduction in storage compared to
untreated Npc1
2/2 controls. This finding was supported by
biochemical analysis of gangliosides in mice treated from P21
(Fig. 5E). Post-weaning treatment rescued Purkinje cells, although
they still showed cholesterol accumulation similar to the Npc1
2/2
mice started on treatment at P7. Overall comparison of post-
weaning treatment to treatment initiated at P7 suggests that
although the latter seems slightly more effective in ameliorating
NPC disease, initiating treatment at later dates still provides
significant benefit to Npc1
2/2 mice.
Chronic treatment of Npc2
2/2 mice with CD ameliorates
storage
Positive results from the CD treatment study in NPC1 disease
led us to hypothesize that Npc2
2/2 mice might also benefit from
treatment, as NPC2 disease is similarly characterized by
cholesterol and GSL accumulation and the two NPC proteins
may function in the same metabolic pathway [9,10]. Npc2
2/2 and
WT mice were administered CD following the same protocol used
for Npc1
2/2 mice receiving chronic, every other day treatment,
albeit at slightly different start dates. Onset of ataxic gait was
delayed from 8 weeks of age in untreated Npc2
2/2 mice to
approximately 10 weeks of age in treated Npc2
2/2 mice. Weight
loss in untreated Npc2
2/2 mice began at approximately 10 weeks
of age, while treated Npc2
2/2 mice did not show weight loss until
13 to 14 weeks of age (Fig. 6A). The average lifespan of an
untreated Npc2
2/2 mouse is approximately 21 weeks of age and
treatment with CD increased longevity by 11 weeks, such that on
average, end-stage occurred at 32 weeks (Fig. 6B).
Filipin labeling of neocortical neurons in treated Npc2
2/2 mice
showed reduced accumulation of unesterified cholesterol and IHC
analysis of gangliosides revealed less GM2 and GM3 storage
(Fig. 6C, D; GM3 not shown). By biochemical quantification
(Fig. 6E), when treatment was initiated between P9 and P22, GM2
and GM3 gangliosides levels studied in mice at 137–150 days of
age were reduced to about half of those in the untreated mice (212
and 241 nmol/g for GM2, 184 and 216 for GM3 in CD-treated
Npc2
2/2 mice versus 413642 and 401634 nmol/g for GM2 and
GM3, respectively in untreated Npc2
2/2 mice; mean 6 SD), and a
significant reduction was still sustained in a 272-day old mouse.
Comparison of age-matched CD-treated and untreated Npc2
2/2
mice revealed less CD68 labeling in brains of treated animals,
suggesting a decrease in neuro-inflammation. Evaluation of end-stage
untreated Npc2
2/2miceandage-matchedCD-treatedNpc2
2/2mice
also revealed more surviving Purkinje cells in the cerebellum of
treated animals, although all remaining Purkinje cells still exhibited
cholesterol accumulation (data not shown). The aforementioned
results are analogous to those found in chronically treated Npc1
2/2
mice and demonstrate that Npc2
2/2mice alsobenefit from treatment
with CD.
Effect of CD treatment on free sphingosine levels in NPC
mice
In normal tissues free sphingoid bases (essentially sphingosine and
sphinganine) are only present in minute amounts, similar to GM2
and GM3 gangliosides in the brain. In NPC patients and animal
models, sequestration of free sphingosine in lysosomes contributes to
the multiple lipid storage pattern, with a many-fold increase in liver,
spleen and fibroblasts, but only a modest increase in brain [11,24–
25]. Free sphingosine is thus another interesting biomarker of NPC
and, due to its free amino group, a putative offending metabolite.
Indeed, Platt and colleagues [26] recently postulated that this
compound might constitute a major factor of cell dysfunction in
NPC. It was therefore also studied in the brains and selected livers of
CD-treated and untreated mice. As shown in Fig. 7A, free
sphingosine levels, already high in the brain of 22-day old Npc1
2/2
mice, increased further to reach a range of 130–180 pmol/mg
protein, compared to 6066 pmol/mg protein in WT mice (mean 6
SD). Very similar levels were found in brains of Npc2
2/2 mice
(Fig. 7A). Early chronic CD treatment normalized the free
sphingosine level in brain of the 22-day old Npc1
2/2 mice, and
significantly reduced values were still observed in mice treated from
the early post-weaning period. A similar (although less pronounced)
t r e n dw a sf o u n df o rNpc2
2/2 mice. The effect of an early one-week
treatment (P7–P14) was,however, not sustained in late stage Npc1
2/2
mice, and chronic treatment starting at P81 was inefficient in
Npc2
2/2 mouse brains. Livers from Npc1
2/2 and Npc2
2/2 mice
showed 10–20 fold increased levels of free sphingosine (Fig. 7B), as
well as of free sphinganine (data not shown), in good accordance to
previously published data [24]. All chronic treatment regimens, even
with a late start, appeared efficient in reducing free sphingosine
accumulation in liver (Fig. 7B). By contrast, one single week of early
treatment from P7 to P14 or P14 to P21 did not result in decreased
levels in an end-stage mouse (Fig. 7B), a result consistent with the
massive storage of cholesterol and sphingomyelin observed in the
livers of those mice (Fig. S4).
Chronic treatment of MPS IIIA and GM1 gangliosidosis
mice with CD does not improve disease state
In addition to NPC disease, several other lysosomal diseases are
characterized by accumulation of cholesterol and GSLs [27]. We
hypothesized thatthesediseasesmight likewise benefitfromtreatment
with CD. Mucopolysaccharidosis type IIIA (MPS IIIA) is caused by a
deficiency in sulfamidase, a lysosomal enzyme necessary for the
catabolism of the glycosaminoglycan, heparan sulfate [28]. In
additionto heparan sulfate storage, neuronsare known to accumulate
G M 2a n dG M 3g a n g l i o s i d e sa n dc h o l e s t e r o l[ 2 9 ] .G M 1g a n g l i o s i -
dosis is also the result of a lysosomal enzymatic deficiency, b-
galactosidase, which catabolizes GM1 to GM2 ganglioside, making
GM1 the primary storage material. Cholesterol accumulation also
occurs secondarilyto that of GM1 in these mice [30] which, however,
do not accumulate significant amounts of GM2 and GM3.
Mice with MPS IIIA and GM1 diseases were treated with CD
using protocols similar to the NPC studies. Since onset of clinically-
evident brain dysfunction is documented to occur later in life for
both mouse models (.5 mos) [31–33], analysis was limited to
changes in brain storage of cholesterol and gangliosides. Short term
studies in the MPS IIIA mice (analogous to the two week study
carried out in the NPC1 mice) did not reveal detectable changes in
either cholesterol or ganglioside (data not shown). Longer duration,
chronic injections of CD also showed no evidence of impact on
storage, even when initiated shortly after weaning (P21 or P30) and
continued for over 3 months in both models (Fig. 8A–E).
Overall, treatment of both MPS IIIA and GM1 mice with CD
showed no detectable benefit in reduction of either cholesterol or
GSL storage. These results differed substantially from the
ameliorating effects of CD treatment in NPC mice, which
included a significant reduction of both cholesterol and GSL
accumulation in treated Npc1
2/2 and Npc2
2/2 mice.
Cyclodextrin in NPC Disease
PLoS ONE | www.plosone.org 8 September 2009 | Volume 4 | Issue 9 | e6951Discussion
The use of combination therapy consisting of NB-DNJ and
allopregnanolone in Npc1
2/2 mice had a synergistic effect in
ameliorating disease progression beyond that seen with either
monotherapy. Additionally, we found that treatment with CD, the
vehicle for allopregnanolone, also provided benefit. As a result, we
re-examined the proposed beneficial effect of allopregnanolone by
utilizing different vehicles or a lower concentration of CD. These
studies showed no significant differences in onset of clinical
disease, in longevity, or in storage of cholesterol and GSLs
between Npc1
2/2 mice receiving allopregnanolone in DMSO or
corn oil compared to vehicle-only controls. Furthermore, while
Npc1
2/2 mice treated weekly with allopregnanolone/5% CD or
Figure 6. Chronic CD treatment study in Npc2
2/2 mice. (A) Average weight over time for untreated and CD-treated Npc2
2/2 and WT mice.
Weights of untreated and CD-treated WTs were averaged for each gender as there was no significant difference between treatments (p,0.8125). (B)
Survival of untreated and CD-treated Npc2
2/2 and WT mice. Median survival of Npc2
2/2 mice: no treatment, 144 days; CD (every other day), 248 days.
CD-treated Npc2
2/2 mice lived significantly longer than untreated Npc2
2/2 mice (p,0.0108). (C) Filipin labeling of unesterified cholesterol in
neocortex of untreated (end-stage, 145 days old) and CD-treated (start at P9; 150 days old) Npc2
2/2 mice revealed less cholesterol accumulation in
the CD-treated mouse. (D) IHC of the same untreated and CD-treated Npc2
2/2 mice showed reduced GM2 labeling in the neocortex of the CD-
treated mouse (also for GM3, not shown). (E) Biochemical analysis of ganglioside levels confirmed the reduction in GM2 and GM3 storage seen with
IHC. Data from WT and mutant mice represent mean 6 SD. Images taken at 20X (C) and 10X (D); scale bars 20 mm (C) and 50 mm (D).
doi:10.1371/journal.pone.0006951.g006
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untreated Npc1
2/2 mice, the two groups did not differ significantly
when compared with each other. Overall these data indicate that
administration of CD (even at low concentrations), has a greater
impact on ameliorating disease progression in NPC1 mice than
does the administration of allopregnanolone without CD. These
findings are further supported by recently published work in which
a single injection of allopregnanolone in CD given to Npc1
2/2
mice did not increase lifespan beyond those mice receiving only
the vehicle, CD [19].
Results from the above studies led us to investigate further the
role of CD in ameliorating disease in treated Npc1
2/2 mice.
Remarkably, Npc1
2/2 mice receiving CD at P7 and then every
Figure 7. Free sphingosine concentrations in NPC disease
following CD treatment. (A) Biochemical analysis of sphingosine in
brain of untreated and CD-treated Npc1
2/2 and WT mice revealed that
chronic CD treatment reduced sphingosine concentrations in affected
mice, even when treatment was initiated post-weaning. Npc2
2/2 mice
exhibited a similar trend, although the effect was less pronounced. (B)
Biochemical analysis of liver from untreated and CD-treated Npc1
2/2
and Npc2
2/2 mice showed that with chronic CD treatment, sphingosine
accumulation was reduced to levels near those found in WT.
doi:10.1371/journal.pone.0006951.g007
Figure 8. Chronic CD treatment study in GM1 and MPS IIIA
mice. (A, B) Filipin labeling of unesterified cholesterol (A) and IHC of
GM1 ganglioside (B) in neocortex of untreated (138 days old) and CD-
treated (start at P21; 138 days old) mice with GM1 gangliosidosis. Brown
punctae indicate GM1 accumulation within cortical neurons. No
differences were observed in either filipin or GM1 labeling between
CD-treated and untreated GM1 mice. (C, D) Filipin labeling of
unesterified cholesterol (C) and IHC of GM2 ganglioside (D) in neocortex
of untreated (140 days old) and CD-treated (start at P30; 140 days old)
MPS IIIA mice. As with GM1 mice, no differences were observed
between CD-treated and untreated MPS IIIA mice. (E) No reductions in
GM1, Asialo-GM1, GM2, or GM3 ganglioside levels were seen in cerebral
homogenates of CD-treated GM1 and MPS IIIA mice compared to
untreated mice as evidenced by the thin-layer chromatography plate.
Images taken at 20X (A, C) and 10X (B, D); scale bars 20 mm (C, also
applicable to A) and 50 mm (D, also applicable to B).
doi:10.1371/journal.pone.0006951.g008
Cyclodextrin in NPC Disease
PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e6951other day for two weeks revealed little to no intraneuronal
accumulation of either cholesterol or gangliosides. Biochemical
analysis also showed that these treated mice exhibited ganglioside
and sphingosine levels comparable to WT controls. Furthermore,
ultrastructural examination of neurons in treated mice revealed
few to no PCBs and no other detectable morphological alterations.
This apparent normalization of most CNS neurons was also
accompanied by expression of the autophagosome marker, LC3-
II, at a level resembling WT, while untreated Npc1
2/2 animals
exhibited a nearly two-fold increase.
Studies examining chronic administration of CD initiated at P7
were found to provide the most significant impact on NPC disease
progression. Treated mice showed delayed onset of ataxic gait and
tremor, significantly increased lifespan, and greatly reduced
accumulation of cholesterol, GSLs, and sphingosine. Treatment
with CD also led to the rescue of some cerebellar Purkinje cells
outside of lobule X as well as a decrease in a marker of neuro-
inflammation, CD68, in the brains of treated Npc1
2/2 mice. LC3-
II levels in the cerebellum of chronically treated Npc1
2/2 mice
were again decreased when compared to untreated controls and
very similar to WT levels, analogous to results of the short term
study. Importantly, Npc1
2/2 mice administered CD beginning
post-weaning (P21–P25) instead of P7 also demonstrated similar
beneficial effects. Finally, comparison of CD-treated Npc1
2/2
mice using different routes of administration suggested that SC
injections were slightly more effective in ameliorating NPC1
disease progression than IP administration. Published research has
shown conflicting results in terms of the benefit of CD in
amelioration of NPC1 disease [16,19,34]. However, our current
results indicate that chronic, every other day treatment with CD,
even when initiated post-weaning, proved significantly more
beneficial than single [16,19] or weekly injections of CD began
at P7 and is the most efficacious of any compound tested to date in
delaying NPC disease.
Confocal analysis of cerebral cortex from chronically-treated
Npc1
2/2 mice revealed that many neurons were essentially devoid
of cholesterol storage whereas neighboring cells sometimes
exhibited significant accumulation. This finding indicates that
CD may impact brain cells differently depending on their type.
Interestingly, while some neurons without cholesterol storage also
lacked GSL storage, many others displayed numerous GM2 and/
or GM3-labeled storage bodies. Cholesterol-sequestering cortical
neurons without accompanying ganglioside storage were not
observed. What these observations mean in terms of a CD
mechanism, or the function of NPC1 and NPC2 proteins, is not
presently known. However, the finding is remarkably similar to
what was observed in studies in which complex ganglioside
synthesis was genetically blocked in NPC1 mice [11,12]. Here,
lack of gangliosides other than GM3 and GD3 led to dramatically
reduced cholesterol storage in cerebral cortex and other brain
areas. Cortical neurons that did persist with cholesterol storage
were found to always accumulate GM3 ganglioside, whereas those
neurons without GM3 lacked evidence of cholesterol sequestration
[12]. While substantial evidence [8,9] supports a direct role for the
NPC1 and NPC2 proteins in cholesterol homeostasis, the
persistence of ganglioside storage in chronically CD-treated NPC
mice, and the apparent dependence of cholesterol sequestration on
GM3 in the studies mentioned, continues to raise questions about
the overall role of gangliosides in NPC disease in relation to
cholesterol sequestration.
Treatment with CD in the NPC1 mouse model has shown
significant beneficial effects on CNS neurons, yet the mechanism
through which these effects are facilitated is unknown. One
important but unresolved issue involves the permeability of the
blood brain barrier (BBB) to CD. CD is a large molecule
(molecular weight<1396 Da) and there are contradictory findings
in terms of its penetration of the BBB. In vivo studies in which mice
were injected intravenously with radiolabeled CD and terminated
1 hour later have suggested that CD does not cross the BBB [34].
Yet a mechanism by which CD could have such striking effects on
brain cholesterol and GSL storage in NPC disease without gaining
direct access to neurons is difficult to envision. Conceivably, CD
may complex with circulating 24S hydroxycholesterol (24S) or
other sterols in the bloodstream and in turn create a ‘‘sink’’ which
might have the ability to enhance cholesterol egress from brain.
Such a mechanism would suggest a feedback loop in which
cholesterol homeostasis within the brain could be influenced by
levels of 24S or other circulating sterols within the bloodstream,
however, no such mechanism is presently known.
Experiments examining cyclodextrins with regard to perme-
ability using an in vitro model of the BBB have indicated that a
small percentage of CD may be transported across the barrier
[35]. Furthermore, there is evidence that use of cyclodextrins as
vehicles for pharmacologic agents significantly facilitates their
entry into brain [16,36]. If CD does enter the brain, it presumably
could exert its impact on cholesterol and GSL accumulation by
acting at the plasmalemma of brain cells or after being
internalized. One scenario, recently suggested by Dietschy and
colleagues, places CD directly in the E/L system of neurons in
Npc1
2/2 mice where it may act as a substitute for the defective
NPC1 protein [19]. This idea implies that after crossing the BBB,
HCD is endocytosed by neurons, complexes with cholesterol in
LEs/LYs and together with the NPC2 protein facilitates
movement of stored cholesterol. However, our studies also indicate
that CD treatment is essentially of equal benefit to NPC2-deficient
mice. This suggests that CD can replace the NPC1 protein, the
NPC2 protein, or an entire cholesterol shuttling mechanism
believed controlled conjointly by the two NPC proteins [9].
Perhaps more likely, if CD reaches the E/L system, it can complex
with compounds other than cholesterol, for example, BMP or
other phospholipids [37] and thereby change E/L membrane
dynamics and cholesterol flux. It has been shown, for example,
that BMP controls the cholesterol storage capacity of late
endosomes [38]. CD may also have the ability to modify the
internal environment of the LE/LY compartment in other ways,
for example, by altering pH [39], and in some manner facilitate
cholesterol flux and/or GSL catabolism. Any of these mechanisms
conceivably could lead to normalized trafficking and clearance of
accumulated cholesterol and GSLs, but all require CD to enter the
neuronal E/L system.
Another scenario to explain the remarkable effect of CD on
cholesterol and GSL storage in neurons, but not requiring direct
access to the E/L system, would be an interaction with cholesterol
at the neuronal plasmalemma. CD is known to have the ability to
extract and deplete cholesterol from the cell membranes [23,37],
the result of which could be a redistribution of cholesterol from the
E/L system to the plasmalemma. This would be consistent with
the view that cholesterol accumulation in NPC cells represents a
dynamic and mobile storage pool [40], with presumably,
redistribution of stored cholesterol allowing secondarily for proper
processing of GSLs. Our finding that CD is beneficial in reducing
cholesterol and GSLs in neurons lacking either NPC1 or NPC2
proteins, but not in neurons in GM1 gangliosidosis or MPS IIIA,
may be revealing of the importance of cholesterol’s mobility in the
NPC-affected cell compared with other lysosomal diseases.
A third potential mechanism of action for CD might involve a
partial or modified BBB penetration. In vitro studies examining the
effects of cyclodextrins on cholesterol removal from macrophage
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shuttle to catalyze the flux of cholesterol between cell membranes
and serum lipoproteins and at high concentrations, it can act as a
sink for cholesterol [41]. Potentially, CD could simply complex
with brain interstitial cholesterol and facilitate its transport into the
circulation. CD could also extract cholesterol from the plasma-
lemma of endothelial cells lining the BBB and either shuttle
cholesterol to acceptor molecules or act as a sink within the
bloodstream as discussed earlier. Alternately, a scenario in which
CD penetrates the BBB but does not enter the neuron could
involve entry into vascular endothelial cells where its effects are
exerted from within these frontline BBB cells, or transcytosis across
these cells followed by endocytosis into adjacent astrocytes.
Astrocytes are known to provide cholesterol to neurons and are
poised to exert significant control over cholesterol homeostasis in
neuronal cells [42–43]. Conceivably, normalization of cholesterol
metabolism within diseased astrocytes could lead to an indirect
normalization of cholesterol pools within neurons. Correction of
the metabolic defect in astrocytes may then allow neurons to
overcome their own metabolic defect, in turn leading to enhanced
processing and trafficking of both cholesterol and GSLs.
Consistent with this scenario, a recent study in which functional
NPC1 protein was expressed in an astrocyte-specific manner in
Npc1
2/2 mice was reported to lead to increased longevity and
decreased neuronal storage of cholesterol [44].
CD is approved for use as a vehicle for drug delivery by several
different routes of administration, including parenteral, oral,
dermal, and transmucosal [45]. Toxicology studies in animal
models, as well as metabolism and pharmacokinetics studies in
humans, have shown CD to be well tolerated and any
histopathological changes to be reversible [46]. Cyclodextrins
are degraded by a-amylases, but those with substituents on the
hydroxyl groups, such as CD, are more resistant to enzymatic
degradation [23]. Futhermore, when administered parenterally, b-
cyclodextrins are excreted almost completely intact in urine. It is
possible that after complexing with cholesterol, CD travels through
the bloodstream to the kidneys, where it is excreted in urine still
complexed with cholesterol. However there were no noticeable
differences in cholesterol accumulation within the kidneys of
chronically-treated versus untreated Npc1
2/2 mice. Examination
of cholesterol storage in livers of treated Npc1
2/2 mice revealed a
shift from hepatocytes, which exhibit remarkable accumulation in
untreated Npc1
2/2 mice, to apparent Kupffer cells in the livers of
CD-treated mice. The cholesterol accumulation in Kupffer cells of
liver from treated Npc1
2/2 mice was also noted in liver from
treated WT mice. Indeed, the livers of CD treated Npc1
2/2 and
WT mice looked remarkably similar in terms of cholesterol
distribution. Analysis of lungs from untreated and CD-treated
Npc1
2/2 mice revealed that cellular cholesterol storage was
present in both groups. However, lungs from a long-term
chronically treated Npc1
2/2 mouse at end-stage (approximately
14 weeks older than the Npc1
2/2 mice mentioned above) had a
consolidated appearance and showed substantial cellular choles-
terol accumulation, raising concerns about possible pulmonary
complications with long-term CD treatment. These studies, as a
whole, suggest that the effects of CD may differ by cell type, for
example, when comparing neurons with hepatocytes or macro-
phage-lineage cells, and that multiple mechanisms of cholesterol
mobilization may be involved.
Although the means by which CD exerts its beneficial effects in
NPC disease are not understood, the outcome of CD treatment is
clearly remarkable. It leads to delay in onset of clinical signs, a
significant increase in lifespan, a reduction in cholesterol and
ganglioside accumulation in neurons, reduced neurodegeneration,
and normalization of markers for both autophagy and neuro-
inflammation. Understanding the mechanism of action for CD will
not only provide key insights into the cholesterol and GSL
dysregulatory events in NPC disease and related disorders, but
may also lead to a better understanding of homeostatic regulation
of these molecules within normal neurons. Furthermore, elucidat-
ing the role of CD in amelioration of NPC disease will likely assist
in development of new therapeutic options for this and other fatal
lysosomal disorders.
Methods
Animals and drug administration
Npc1
2/2 mice, along with WT littermates, were generated by
crossing Npc1
+/2 males and females in-house. The NPC1 mouse
(BALBc/NPC
nih) was originally obtained from Peter Penchev at
the National Institutes of Health (Bethesda, MD). Mouse pups
were gentoyped according to published protocols [47] and WT
and Npc1
2/2 mice were enrolled in the combination treatment
study. Starting at P7 and weekly thereafter, some mice were
injected SC with either 20% CD (control; 4000 mg/kg; H107,
Sigma Aldrich, St. Louis, MO) or allopregnanolone (dissolved in
20% CD; 25 mg/kg; P3800-000, Steraloids, Newport, RI).
Additionally, some mice were injected IP every day starting at
P10 until P23 with either saline (control; 0.9% normal saline;
104 6816, Fisher Scientific, Waltham, MA) or miglustat (dissolved
in saline; 300 mg/kg; a gift from Oxford GlycoSciences,
Abingdon, UK/Celltech UK, Slough, Berkshire, UK). Following
weaning at P23, miglustat and combination treated mice were
housed individually in cages and fed powdered chow (Lab Diet
5058, PMI Nutrition International, LLC, Brentwood, MO) to
which miglustat was added daily (1200 mg/kg) [14]. Npc1
2/2
mice, along with WT controls, were terminated when mice had at
least two of the three signs considered to be end-stage disease.
Clinical signs of end-stage disease included hunched posture and
reluctance to move about the cage, inability to remain upright
when moving forward, and weight loss greater than 30% of peak
weight (mean end-stage weight=14.3 g). Npc1
2/2 and WT mice
placed in the CD treatment studies were administered SC or IP
injections of 20% CD (4000 mg/kg) beginning at either P7 or
shortly after weaning (P21–P25). Injections were continued every
other day until sacrifice. Npc2
2/2, MPS IIIA, and GM1 mice,
along with WT littermates, were generated by crossing heterozy-
gotes from in-house colonies of each disease model. Like NPC1
mice, the NPC2 mouse model is also on a uniform background
[BALB/c; 10]. The MPSIIIA model is of mixed genetic
background, consisting mainly of C57BL/6 with contributions
from 129SvJ, CD1, and SJL mouse strains [32]. The GM1 colony
also has a mixed genetic background with the major contributing
strain being C57BL/6 [31]. These animals were treated with CD
using the same protocol as for Npc1
2/2 mice, the only variation
being the date of first injection, which ranged from P7 to P30.
Treated Npc1
2/2 and Npc2
2/2 mice, along with WT littermates,
were sacrificed at end-stage or with age-matched untreated controls
forcomparison.MPSIIIA and GM1mice plus WTlittermateswere
sacrificed after approximately 3 months of treatment with CD,
along with untreated controls. Mice were deeply anesthetized with
an IP injection of sodium pentobarbital (150 mg/kg) and when
insensate, were transcardially perfused with 0.9% saline solution.
Following perfusion, a craniotomy was performed and the right
cerebrum and right half of cerebellum were removed, along with
liver and kidney, which were immediately frozen at 280uC for
biochemical analyses. Mice were re-perfused with 4% paraformal-
dehyde in 0.1M phosphate buffer (PB) and additional tissues were
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and immersion fixed overnight in 4% paraformaldehyde/PB.
Tissues were rinsed the following day and stored in PB at 4uC.
All animal procedures were carried out according to guidelines
approved by the Einstein College of Medicine Institutional Animal
Care and Use Committee.
Statistical analyses
JMPH software (JMPH, Version 7. SAS Institute Inc., Cary, NC)
was used to analyze weight data from Npc1
2/2 and Npc2
2/2 mice
in the treatment studies. There were no significant differences in
weight between untreated and CD-treated WT mice, as Repeated
Measures ANOVA revealed no main effect of treatment
(Ftreatment=0.0027; p,0.8125) and no interactions between
treatment and time (Ftreatment6time=0.4812; p,0.2041). There
were also no significant differences between untreated and CD-
treated WT weights when individual t-tests were performed at
each time point. To determine if statistically significant differences
between lifespan of treated and untreated groups occurred, a
survival analysis using a Log-rank (Mantel-Cox) Test was
performed in GraphPad Prism (GraphPad Software version
5.01, San Diego California USA).
Antibodies and reagents
The following primary antibodies were purchased for use in
immunohistochemistry and/or immunofluorescence: anti-GM3
ganglioside mAb (DH2, mouse IgG3, cell culture supernatant; 10-
011; GlycoTech); anti-GM1 ganglioside pAb (IgG, serum; G2006-
11; US Biological, Swampscott, MA); anti-CD68 mAb (rat IgG;
MCA1957; AbD Serotec, Raleigh, NC); anti-calbindin mAb
(mouse IgG, C9848) (Sigma-Aldrich, St. Louis, MO); and anti-
LC3 pAb (rabbit IgG, NB100-2220; NOVUS Biologicals,
Littleton, CO). Anti-GM2 ganglioside mAb (Mouse IgM, cell
culture supernatant) was produced in-house from the 10–11
hybridoma line provided by Progenics Pharmaceuticals, Inc.
(Tarrytown, NY). BC-theta was provided by Dr. Y. Ohno-
Iwashita (Cellular Signaling Group, Tokyo Metropolitan Institute
of Gerontology, Japan) (Iwamoto, 1997).
The following secondary antibodies and reagents were pur-
chased for use in immunoperoxidase staining: biotinylated goat
anti-mouse IgM (BA-2020), biotinylated goat anti-mouse IgG (BA-
9200), biotinylated goat anti-rabbit IgG (BA-1000), Vectastain
ABC kit (PK-4000), and DAB Peroxidase Substrate Kit (SK-4100)
from Vector Laboratories (Burlingame, CA). The following
secondary and tertiary antibodies were purchased for use in
immunofluorescence: FITC-conjugated goat anti-mouse IgG (c
specific-Fc, 55517) from MP Biomedicals (Solon, OH); Alexa
Fluor 633-conjugated goat anti-mouse IgM (m chain, A21046),
Alexa Fluor 546-conjugated streptavidin (S11225), and Alexa
Fluor 488 Signal-Amplification Kit for FITC-conjugated probes
(A11053) from Molecular Probes/Invitrogen (Carlsbad, CA).
Filipin complex from Streptomyces filipinensis (F9765) was purchased
from Sigma-Aldrich (St. Louis, MO). Peroxidase-labeled goat anti-
rabbit IgG (PI-1000) was purchased from Vector Laboratories
(Burlingame, CA) for use in western blotting.
Immunohistochemical and filipin staining procedures
Immunoperoxidase staining was carried out according to
previously published protocols [29]. Primary antibody dilutions
were as follows: anti-GM2 (1:5), anti-GM3 (1:50), anti-GM1
(1:5000), anti-calbindin (1:3000), and anti-CD68 (1:200). Second-
ary antibody dilutions were 1:200 for biotinylated goat anti-mouse
IgM, biotinylated goat anti-mouse IgG, and biotinylated goat anti-
rabbit IgG.
Immunofluorescence was carried out according to previously
published protocols [29]. Primary antibodies were diluted
according to: anti-GM2 (1:5), anti-GM3 (1:5), and BC Theta
(8 mg/ml). Secondary antibodies were diluted as follows: FITC-
conjugated goat anti-mouse IgG (1:200), Alexa Fluor 633-
conjugated goat anti-mouse IgM (1:300), Alexa Fluor 546-
conjugated streptavidin (1:750) and Alexa Fluor 488 Signal-
Amplification Kit component A (1:80). To visualize unesterified
cholesterol, sections were incubated with filipin complex (0.005%
dissolved in DMSO and diluted in PBS) or DMSO (control;
diluted in PBS) and labeling was carried out according to
previously cited protocols.
Imaging procedures
Brightfield images were obtained using an upright Olympus
AX70 microscope and MagnaFire camera. Images of filipin
labeling were obtained on the same Olympus microscope but
utilizing settings appropriate for acquisition of fluorescent images.
Laser scanning confocal fluorescence images were obtained on a
Zeiss 510 Duo V2 system using a 63X oil objective (NA=1.4) and
a zoom setting of 3. A multi-track mode, optimized for each
fluorophore combination, was employed to help ensure no
channel cross-talk. Digital images were further prepared for
presentation using Metamorph software (Molecular Devices) and
Adobe Photoshop.
Electron microscopy
According to published protocols [32], fixed tissues were
transferred to 0.1M cacodylate buffer, post-fixed in 2% glutaral-
dehyde, washed and post-fixed in osmium (1% osmium in 0.1%
cacodylate buffer), dehydrated and embedded in Epon-aryldite.
Ultrathin sections were cut from the plastic embedded blocks,
stained with uranyl acetate and lead citrate, and examined with a
Philips CM10 electron microscope.
Biochemical lipid and protein analyses
Lipid analyses were carried out on frozen cerebral hemispheres
and liver. Total lipid extracts were obtained as in Fujita et al. [48].
The procedures for ganglioside isolation and subsequent quanti-
tation were as in previous studies [10,49]. Analysis of free
sphingoid bases was carried out by high-performance liquid
chromatography as described by Rodriguez-Lafrasse et al. [25]
using eicosasphinganin as an internal standard. Separation of o-
phtalaldehyde derivatives was achieved on a 20064.9 mm, 5 mm
Spherisorb ODS2 column (Waters) and monitored by fluorometry.
Western blot analysis of LC3 was carried out according to the
following method. Frozen brain tissue was homogenized in ice-
cold lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1%
Igepal CA-630, 1% deoxycholic acid, 0.1% SDS supplemented
with protease inhibitor cocktail), centrifuged (15000 rpm) for 30
minutes at 4uC and the supernatants (soluble fraction) were
collected. Protein concentrations were determined using a BCA
protein assay kit. For immunoblotting, samples were analyzed by
SDS-PAGE (16% gels) under reducing conditions and transferred
to Immuno-blot PVDF membranes. Membranes were blocked in
1x TBS, 0.1% Tween-20, 5% non-fat dry milk, 1% BSA, followed
by incubation with an antibody to LC3 (2 mg/ml) and subsequent
incubation with Peroxidase Labeled anti-Rabbit IgG secondary
antibody (1:5000). SuperSignal West Pico Chemiluminescent
Substrate was used for protein detection on a KODAK 2000R
imaging station. Protein quantification for each sample was
performed by densitometric analysis using KODAK imaging
software and normalized to actin in the same sample. This analysis
Cyclodextrin in NPC Disease
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untreated control.
Supporting Information
Figure S1 Route of administration of CD in Npc1
2/2 mice. (A,
B) Filipin labeling of unesterified cholesterol (A) and IHC of GM2
ganglioside (B) in neocortex of 22 day old Npc1
2/2 untreated (left
panels) and CD-treated mice injected either SC (middle panels) or
IP (right panels) starting at P7. Results indicated that while both
routes of administration reduced cholesterol accumulation com-
pared to untreated Npc1
2/2 mice, SC injections seemed to be
more efficacious than IP injections. Images taken at 20X (A) and
10X (B); scale bars 20 mm (A) and 50 mm (B).
Found at: doi:10.1371/journal.pone.0006951.s001 (4.05 MB TIF)
Figure S2 Cholesterol accumulation in visceral tissues from
chronic CD treatment study in Npc1
2/2 mice. (A, B, C) Filipin
labeling of unesterified cholesterol in kidney (A), liver (B), and lung
(C) from untreated Npc1
2/2 (end-stage, 87 days old; first column),
CD-treated Npc1
2/2 (age-matched, 90 days old; second column),
CD-treated Npc1
2/2 (end-stage, 223 days old; third column),un-
treated (87 days old, fourth column) WT, and CD-treated WT (90
days old; fifth column) mice. No obvious differences were seen
between cholesterol accumulation in kidneys of untreated versus
CD-treated Npc1
2/2 mice (A). Filipin labeling indicated a shift of
cholesterol storage from hepatocytes in untreated Npc1
2/2 mice to
presumptive Kuppfer cells in CD-treated Npc1
2/2 mice, an
observation also noted in CD-treated WT mice (B). Overall, filipin
labeling of lung from both untreated and CD-treated Npc1
2/2
mice suggested the presence of more cholesterol accumulation
than in lung from WT mice (C). Images taken at 20X; scale bar
20 mm (C, also applicable to A and B).
Found at: doi:10.1371/journal.pone.0006951.s002 (4.65 MB TIF)
Figure S3 H&E staining of visceral tissues from chronic CD
treatment study in Npc1
2/2 mice. (A, B, C) H&E staining of
kidney (A), liver (B), and lung (C) from untreated and CD-treated
Npc1
2/2 and WT mice (same mice as in Fig. S2). No obvious
differences were noted in kidney between untreated and CD-
treated mice (A). Staining of liver indicated the presence of lipid
laden hepatocytes within untreated Npc1
2/2 tissue but these were
not noted in any other mice (B). While macrophages were present
in lung tissue from both untreated and CD-treated Npc1
2/2 mice,
CD-treated mice showed increasing macrophage infiltration,
especially as CD treatment continued to end-stage disease.
Lipid-laden macrophages were not observed in either untreated
or CD-treated WT tissue (C). Images taken at 20X; scale bar
20 mm (C, also applicable to A and B).
Found at: doi:10.1371/journal.pone.0006951.s003 (8.44 MB TIF)
Figure S4 Effect of chronic CD treatment on lipid storage in
liver of Npc1
2/2 mice. (A) Thin layer chromatographic profile of
total lipids in liver tissue of Npc1
2/2 or WT mice, untreated
(Unt’d) or CD-treated for the indicated period, visualized with the
anisaldehyde reagent. Results indicate that chronic CD treatment,
but not 1 week of early CD treatment (far right lane), normalizes
lipid storage (Chol, GlcCer, BMP, and Sph) in Npc1
2/2 liver to
levels near WT. The amount of lipid extract spotted corresponded
to 2 mg wet tissue. Chol: unesterified cholesterol; GlcCer:
glucosylceramide; BMP: bis(monoacylglycero)phosphate; Sph:
sphingomyelin.
Found at: doi:10.1371/journal.pone.0006951.s004 (1.34 MB TIF)
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